Grail cancer blood test approval discussions expected

Barron’s says this week’s 35% jump in Grail stock reflects a positive vote ahead of an FDA meeting with outside experts about approving the first blood test for many kinds of cancer; Grail is described as valued at $4.3 billion (19x the co…).